Migraine And Headache
For abortive medications, results showed that overall 18.9% of patients received all high quality abortive medication, 27% received some low quality abortive while 15.2% received opioids.
Results showed that a statistically significant number of those participants who received lasmiditan (in all doses) were pain-free at 2-hours post dosage compared to those who received placebo (the primary endpoint).
The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress.
The use of complementary and alternative medicine (CAM) specifically for the treatment of migraine and headache is "relatively low" in the U.S.
If approved by the FDA, Aimovig will be the first monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor specifically intended for migraine prophylaxis.
The Food and Drug Administration (FDA) approved gammaCore in April after efficacy was demonstrated in two clinical trials involving over 200 patients with episodic cluster headaches (ACT1 and ACT2).
The study findings suggest that telemedicine may be valuable for headache sufferers who want to see a specialist without extra hassle or inconvenience, he said.
Results showed that after three months, the use of Cefaly was associated with a statistically significant, albeit small, reduction in the number of headache days.
Patients in the galcanezumab group had statistically significant greater reduction in monthly migraine headache days with acute medication use compared to placebo.
The HALO Clinical Research Program consists of two 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies that compared fremanezumab to placebo in adults with episodic and chronic migraine.
Amgen announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for erenumab for the prevention of migraines.
The authors concluded that for adult prophylaxis, riboflavin "is well tolerated, inexpensive and most controlled clinical trials have shown modest reductions in migraine headache frequency."
Lilly announced encouraging results from three Phase 3 studies of galcanezumab, EVOLVE-1, EVOLVE-2 and REGAIN, evaluating its efficacy and safety for the prevention of episodic and chronic migraine.
Tepper, Stewart et al. "Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial". DOI: 10.1016/S1474-4422(17)30083-2.
Results met the primary endpoint of a significant reduction in migraine days for the eptinezumab groups, as measured by 75% responder rates.
In August 2016, the FDA granted tentative approval of the Company's one of two supplemental New Drug Applications (sNDAs). The final approval was contingent on the pediatric exclusivity of the drug in the adolescent population that expired March 28, 2017.
Researchers found that compared to patients who had migraine with aura, those who had migraine without aura were 1.74 times more likely to have CEAD.
In this study, researchers reviewed the evidence on the use of IN administration for several medications commonly used in the emergency department.
Zosano has announced positive results from their Phase 3 clinical trial of M207, the companies lead candidate for the treatment of migraine attacks.
Migraine sufferers may face a slightly higher risk of stroke after an operation, according to research published online January 10 in The BMJ.
For children and adolescents with migraine, amitriptyline and topiramate do not reduce headache frequency or headache-related disability more than placebo, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Child Neurology Society, held from October 26 to 29 in Vancouver, Canada.
Endo Pharmaceuticals has informed the Food and Drug Administration (FDA) of the discontinuation of Sumavel DosePro (sumatriptan injection), in the 4mg/0.5mL formulation.